This Research & Innovation Action under Horizon Europe will validate surgery-centred, multi-modal treatment strategies—including minimally invasive techniques combined with medical devices or adjunct therapies—in academic investigator-initiated clinical trials for patients with locally advanced or metastatic solid tumours. Projects must demonstrate clinical effectiveness, patient-reported outcomes, quality of life improvements and cost-effectiveness across diverse European healthcare settings, with open-science data sharing via UNCAN.eu.
Eligibility Criteria:
- Consortium of ≥3 independent legal entities from Horizon Europe Member States or Associated Countries
- Academic lead partners capable of sponsoring and running investigator-initiated clinical trials
- Inclusion of multidisciplinary stakeholders (surgeons, clinicians, patients/caregivers, SMEs, health economists, SSH experts)
- Commitment to sex-/gender-disaggregated data and socio-economic/cultural diversity in trial design
- Plans for cost-effectiveness analysis and metadata registration in the European Health Data Space
Funding Details:
- Action Type: HORIZON-RIA (Research & Innovation Action)
- Total Budget: 31 000 000 EUR
- Indicative Grants: 4 grants of 7 000 000 EUR – 10 000 000 EUR each
- Model: Single-stage, budget-based action grant
Deadline:
Submit via the EU Funding & Tenders Portal by 16 September 2025, 17:00 Brussels time.
Where to Apply & More Info:
- EU Funding & Tenders Portal – search HORIZON-MISS-2025-02-CANCER-03